WO2023059121A1 - 신규한 벤조퓨라닐 히드록시페닐 메타논 유도체 화합물 또는 이의 약학적으로 허용가능한 염 - Google Patents
신규한 벤조퓨라닐 히드록시페닐 메타논 유도체 화합물 또는 이의 약학적으로 허용가능한 염 Download PDFInfo
- Publication number
- WO2023059121A1 WO2023059121A1 PCT/KR2022/015097 KR2022015097W WO2023059121A1 WO 2023059121 A1 WO2023059121 A1 WO 2023059121A1 KR 2022015097 W KR2022015097 W KR 2022015097W WO 2023059121 A1 WO2023059121 A1 WO 2023059121A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methanone
- formula
- hydroxyphenyl
- compound
- dibromo
- Prior art date
Links
- -1 benzofuranyl hydroxyphenyl methanone derivative compound Chemical class 0.000 title claims abstract description 118
- 150000003839 salts Chemical class 0.000 title claims abstract description 38
- 150000001875 compounds Chemical class 0.000 claims abstract description 81
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 28
- 230000004761 fibrosis Effects 0.000 claims abstract description 28
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 13
- 201000011510 cancer Diseases 0.000 claims abstract description 13
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 6
- 101000836383 Homo sapiens Serpin H1 Proteins 0.000 claims abstract 11
- 102100027287 Serpin H1 Human genes 0.000 claims abstract 11
- 230000002401 inhibitory effect Effects 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 125000001246 bromo group Chemical group Br* 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 claims description 4
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 208000002260 Keloid Diseases 0.000 claims description 3
- 206010023330 Keloid scar Diseases 0.000 claims description 3
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 3
- 230000001969 hypertrophic effect Effects 0.000 claims description 3
- 210000001117 keloid Anatomy 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 3
- 231100000241 scar Toxicity 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- SKQZNDJMQJDTOE-UHFFFAOYSA-N (4-chloro-2-ethyl-1-benzofuran-3-yl)-(3,5-dibromo-4-hydroxyphenyl)methanone Chemical compound CCC=1OC2=CC=CC(Cl)=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 SKQZNDJMQJDTOE-UHFFFAOYSA-N 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010010741 Conjunctivitis Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 206010033078 Otitis media Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 201000007100 Pharyngitis Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 201000003146 cystitis Diseases 0.000 claims description 2
- 201000005917 gastric ulcer Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 201000002793 renal fibrosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 206010044008 tonsillitis Diseases 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 abstract description 26
- 238000002360 preparation method Methods 0.000 abstract description 15
- 239000000126 substance Substances 0.000 abstract description 13
- 230000002265 prevention Effects 0.000 abstract description 5
- 108010055039 HSP47 Heat-Shock Proteins Proteins 0.000 description 38
- 102000001214 HSP47 Heat-Shock Proteins Human genes 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 13
- 102000000018 Chemokine CCL2 Human genes 0.000 description 13
- 102000008186 Collagen Human genes 0.000 description 12
- 108010035532 Collagen Proteins 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 229920001436 collagen Polymers 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 239000000829 suppository Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 210000004024 hepatic stellate cell Anatomy 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000003125 aqueous solvent Substances 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 210000001626 skin fibroblast Anatomy 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000010520 demethylation reaction Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 2
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 2
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 235000001046 cacaotero Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000010149 post-hoc-test Methods 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- QJDUDPQVDAASMV-UHFFFAOYSA-M sodium;ethanethiolate Chemical compound [Na+].CC[S-] QJDUDPQVDAASMV-UHFFFAOYSA-M 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- YUTFQTAITWWGFH-UHFFFAOYSA-N 1-(1-benzofuran-2-yl)ethanone Chemical compound C1=CC=C2OC(C(=O)C)=CC2=C1 YUTFQTAITWWGFH-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- MFJCKQFUMBQBDU-UHFFFAOYSA-N 1-benzofuran-2-yl-(4-hydroxyphenyl)methanone Chemical class C1=CC(O)=CC=C1C(=O)C1=CC2=CC=CC=C2O1 MFJCKQFUMBQBDU-UHFFFAOYSA-N 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- VTUQUFMGCUGNMW-UHFFFAOYSA-N 2-(1-benzofuran-2-yl)benzoic acid Chemical class OC(=O)C1=CC=CC=C1C1=CC2=CC=CC=C2O1 VTUQUFMGCUGNMW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QNZWAJZEJAOVPN-UHFFFAOYSA-N 4-chloro-2-hydroxybenzaldehyde Chemical compound OC1=CC(Cl)=CC=C1C=O QNZWAJZEJAOVPN-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000011594 Autoinflammatory disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 239000011547 Bouin solution Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N benzofuran Natural products C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000004653 carbonic acids Chemical class 0.000 description 1
- 150000001734 carboxylic acid salts Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 150000001907 coumarones Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 125000004385 trihaloalkyl group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000003424 uricosuric effect Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
Definitions
- the present invention relates to a novel benzofuranyl hydroxyphenyl methanone derivative compound, and more particularly, to a pharmaceutical composition for inhibiting HSP47 containing a benzofuranyl hydroxyphenyl methanone derivative and a method for preparing the same.
- HSP47 Heat shock protein 47 protein is a protein present in the endoplasmic reticulum induced by stress and acts as a chaperone protein for the formation of a three-dimensional structure of collagen and its extracellular secretion. It has been reported that the expression of HSP47 is increased in fibrosis of various tissues such as liver cirrhosis, pulmonary fibrosis, keloid, hypertrophic scar and glomerulosclerosis. According to the literature, it has been reported that inhibition of HSP47 protein suppresses collagen secretion in cells producing collagen secretion. In addition, it has been reported that inhibition of HSP47 protein induces apoptosis of cells producing collagen (Ito S et. al ., 2017). These results suggest that inhibition of HSP47 protein is an effective and specific therapeutic target for anti-fibrosis treatment.
- Fibrosis or fibrosis refers to the abnormal accumulation of collagen following injury or inflammation that alters the structure and function of various tissues. Regardless of where the fibrosis occurs, most etiologies of fibrosis involve excessive accumulation of collagen replacing normal tissue. Progressive fibrosis in liver, lung or skin is a disease with high unmet medical need for which there is no specific treatment to date.
- HSP47 function of HSP47 is not limited to collagen production, but promotes inflammation and angiogenesis by promoting the expression of MCP-1 (Monocyte chemoattractant protein-1), one of the inflammatory mediating proteins, in bladder cancer cells, which are cancer cells (Ma Wenlong et al . et al., 2021).
- MCP-1 Monocyte chemoattractant protein-1
- bladder cancer cells which are cancer cells (Ma Wenlong et al . et al., 2021).
- HSP47 has also been reported to be expressed in cancer cells, and it has been reported that increased expression of HSP47 facilitates the metastasis of many cancer cells regardless of the presence or absence of collagen expression, thereby increasing mortality. It has also been reported that suppression of HSP47 expression by genetic methods suppresses cancer progression (Parveen A et. al., 2020).
- Benzofurans. XXXI Relation of structure to uricosuric activity of certain p-hydroxybenzoylbenzofurans in the human By: Delbarre, Florian; Deltour, Guy; Rose, Alain; Olivier, J. L.; Binon, Fernand Chimica Therapeutica (1968), 3(6), 470-4
- HSP47 contributes to angiogenesis by induction of CCL2 in bladder cancer Cell Signal. 2021 85:110044.
- An object to be solved by the present invention is to recognize that there is a close relationship between HSP47 and excessive accumulation of collagen, and to provide an HSP47 inhibitor having therapeutic efficacy against diseases such as fibrosis and cancer by inhibiting HSP47 protein.
- an object of the present invention is to provide a pharmaceutical composition for preventing or treating HSP47-related diseases comprising the benzofuranyl hydroxyphenyl methanone derivative compound as an active ingredient.
- Another object of the present invention is to provide a method for preventing or treating HSP47-related diseases using the benzofuranyl hydroxyphenyl methanone derivative compound or a pharmaceutically acceptable salt thereof.
- Another object of the present invention is to provide a use for preventing or treating HSP47-related diseases of the benzofuranyl hydroxyphenyl methanone derivative compound or a pharmaceutically acceptable salt thereof.
- Another object of the present invention is to provide a method for preparing the benzofuranyl hydroxyphenyl methanone derivative compound or a pharmaceutically acceptable salt thereof.
- a benzofuranyl hydroxyphenyl methanone derivative compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof is provided.
- R 1 and R 2 are halogen
- R 3 is hydrogen or C 1 -C 3 alkyl
- R a , R b and R d are independently hydrogen, C 1 -C 3 alkyl or halogen
- R c is hydrogen, C 1 -C 3 alkyl, halogen or C 1 -C 3 haloalkyl.
- a pharmaceutical composition for preventing or treating HSP47-related diseases comprising the benzofuranyl hydroxyphenyl methanone derivative compound represented by Formula I or a pharmaceutically acceptable salt thereof as an active ingredient Provided.
- a method for preventing or treating HSP47-related diseases using the benzofuranyl hydroxyphenyl methanone derivative compound represented by Formula I or a pharmaceutically acceptable salt thereof is provided.
- preparing a compound of formula I-2 from a compound of formula I-1 by a nucleophilic substitution reaction comprising the step of obtaining a compound of the following formula (I) from the obtained compound of the formula (I-5): Provided.
- R 1 , R 2 , R 3 , R a , R b , R c and R d is the same as defined above.
- the benzofuranyl hydroxyphenyl methanone derivative compound represented by Formula I inhibits collagen accumulation in the liver, lungs, kidneys, skin tissues, etc., and kills cells that excessively produce collagen in a diseased state. It has been found that by showing an HSP47 inhibitory effect, it can be used for HSP47 inhibitory purposes such as prevention or treatment of fibrosis and cancer.
- the benzofuranyl hydroxyphenyl methanone derivative compound of the present invention can be usefully used for HSP47 inhibition such as prevention or treatment of fibrosis and cancer in the field of medicine and pharmacology.
- the present invention provides a benzofuranyl hydroxyphenyl methanone derivative compound represented by the following formula (I), or a pharmaceutically acceptable salt thereof.
- R 1 and R 2 are halogen
- R 3 is hydrogen or C 1 -C 3 alkyl
- R a , R b and R d are independently hydrogen, C 1 -C 3 alkyl or halogen
- R c is hydrogen, C 1 -C 3 alkyl, halogen or C 1 -C 3 haloalkyl.
- R 1 and R 2 may be bromo or iodine.
- R 3 may be a substituent selected from the group consisting of hydrogen, methyl, and ethyl.
- R a may be a substituent selected from the group consisting of hydrogen, methyl, fluoro and chloro.
- R b may be a substituent selected from the group consisting of hydrogen, methyl, ethyl and bromo.
- R c may be a substituent selected from the group consisting of hydrogen, methyl, ethyl, trifluoromethyl, chloro and bromo.
- R d may be a substituent selected from the group consisting of hydrogen, methyl, ethyl, fluoro, chloro and bromo.
- alkyl is a straight-chain or branched-chain saturated hydrocarbon, preferably C1-C10 alkyl.
- the alkyl is methyl, ethyl, n- propyl, iso- propyl, n -butyl, iso- butyl, tert- butyl, n -pentyl, iso- pentyl, n- hexyl, 3-methylhexyl, 2, 2-dimethylpentyl, 2,3-dimethylpentyl, n- heptyl, n-octyl, n - nonyl and n- decyl; and the like.
- halogen or halo means fluorine/fluorine (F), chlorine (Cl), bromine (Br), or iodine (I).
- haloalkyl refers to an alkyl group in which one or more hydrogen atoms have been replaced by a halogen (eg, mono-haloalkyl, di-haloalkyl, and tri-haloalkyl).
- halogen eg, mono-haloalkyl, di-haloalkyl, and tri-haloalkyl.
- groups include, but are not limited to, chloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 1-chloro-2-fluoromethyl and 2-fluoroisobutyl.
- the compound represented by Formula I according to the present invention can be used in the form of a prodrug, hydrate, solvate, or pharmaceutically acceptable salt in order to improve absorption or solubility in vivo
- the prodrug, Hydrates, solvates and pharmaceutically acceptable salts are also within the scope of this invention.
- prodrug refers to a substance that is transformed into the parent drug in vivo. Prodrugs are often used because, in some cases, they are easier to administer than the parent drug. For example, they may obtain bioactivity by oral administration whereas the parent agent may not. A prodrug may also have improved solubility in a pharmaceutical composition than the parent drug.
- a prodrug may be an in vivo hydrolyzable ester of a compound according to the present invention and a pharmaceutically acceptable salt thereof.
- Another example of a prodrug would be a short peptide (polyamino acid) attached to an acid group that is metabolized to reveal an active site.
- hydrate refers to a compound of the present invention that contains a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces. or a salt thereof.
- solvate refers to a compound of the present invention or a salt thereof that contains a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces.
- Preferred solvents in this regard are those that are volatile, non-toxic, and/or suitable for administration to humans.
- isomers refers to compounds of the present invention or salts thereof that have the same chemical formula or molecular formula but differ structurally or sterically. These isomers include both structural isomers such as tautomers, R or S isomers having an asymmetric carbon center, and stereoisomers such as geometric isomers (trans, cis). All these isomers and mixtures thereof are also included within the scope of the present invention.
- pharmaceutically acceptable salt refers to a salt form of a compound that does not cause serious irritation to the organism to which the compound is administered and does not impair the biological activity and physical properties of the compound.
- the pharmaceutical salt is an acid that forms a non-toxic acid addition salt containing a pharmaceutically acceptable anion, for example, inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydroiodic acid, tartaric acid, formic acid, Organic carbonic acids such as citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, maleic acid, salicylic acid, etc., methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc.
- inorganic acids such as hydrochloric acid, sulfuric acid, nitric
- carboxylic acid salts include metal salts or alkaline earth metal salts formed by lithium, sodium, potassium, calcium, magnesium, etc., amino acid salts such as lysine, arginine, guanidine, dicyclohexylamine, N- organic salts such as methyl-D-glucamine, tris(hydroxymethyl)methylamine, diethanolamine, choline and triethylamine; and the like.
- the compounds of formula I according to the present invention may be converted into their salts by conventional methods.
- the present invention provides a method for preparing the above formula (I), and includes the following steps.
- This step is a reaction of synthesizing a benzofuran ring compound by reacting the compound of Formula I-1 with chloroacetone in the presence of potassium carbonate.
- the solvent used at this time can be a solvent commonly used in nucleophilic substitution, for example, acetone, tetrahydrofuran, N, N-dimethylformamide, etc., at an appropriate temperature (eg 70 °C) for an appropriate reaction time (eg, about 6 hours) to obtain the compound of Formula I-2.
- This step is a reaction in which the ketone of the obtained compound of Formula I-2 is reduced using hydrazine and potassium hydroxide.
- a reaction time eg, about 1 hour
- the obtained benzofuran compound of Chemical Formula I-3 is reacted with 4-anizoyl chloride (4-methoxybenzoyl chloride) and tin tetrachloride (SnCl 4 ), which is a Lewis acid, to obtain the following Chemical Formula I It is a Friedelcrafts acylation reaction to obtain the compound of -4.
- the solvent used at this time may be a solvent commonly used in the Friedel-Crafts acylation reaction, for example, dichloromethane or carbon disulfide.
- This step may be 1) a demethylation reaction using sodium ethanethiolate, or 2) a demethylation reaction using boron tribromide.
- the reaction using sodium ethanethiolate of 1) may mainly proceed in a N,N-dimethylformamide solvent, but is not limited thereto.
- the demethylation reaction using boron tribromide in the second method 2) may mainly proceed in a dichloromethane solvent, but is not limited thereto.
- This step is a reaction for introducing two bromo groups or iodine groups into the obtained compound of Formula I-5.
- the reaction for introducing a bromo group is carried out by adding bromine or N-bromosuccinimide to the compound of Formula I-5 below.
- the solvent used at this time is carried out using a solvent commonly used in the bromination reaction, for example, dichloromethane or acetone.
- the reaction to introduce an iodine group can be obtained by reacting a compound of Formula I-5 with iodine and silver nitrate.
- the solvent used at this time may be mainly alcohol solvents such as ethanol, but is not limited thereto.
- R 1 , R 2 , R 3 , R a , R b , R c and R d is the same as defined above.
- Reaction Schemes 1 to 24 of Examples are exemplified as a method for preparing the compound of Formula I of the present invention, and the method for preparing the compound of Formula I according to the present invention is not limited to the preparation method of these Reaction Schemes 1 to Scheme 24.
- the preparation methods of Reaction Scheme 1 to Reaction Scheme 24 are only examples, and it is obvious that they can be easily modified by a person skilled in the art according to specific substituents.
- the present invention also provides a pharmaceutical composition for inhibiting HSP47 comprising, as an active ingredient, the benzofuranyl hydroxyphenyl methanone derivative compound represented by Formula I or a pharmaceutically acceptable salt thereof.
- the present invention also relates to the prevention of related diseases for the purpose of inhibiting HSP47, comprising administering to a patient a therapeutic dose of the benzofuranyl hydroxyphenyl methanone derivative compound represented by Formula I, or a pharmaceutically acceptable salt thereof. or a method of treatment.
- the present invention also provides a use of the benzofuranyl hydroxyphenyl methanone derivative compound represented by Formula I, or a pharmaceutically acceptable salt thereof, for the purpose of inhibiting HSP47.
- the agent for inhibiting HSP47 may be for preventing or treating fibrosis that can be achieved by inhibiting HSP47.
- the fibrosis may be one or more selected from the group consisting of liver cirrhosis, pulmonary fibrosis, keloid, hypertrophic scar, and renal fibrosis (glomerular sclerosis).
- the HSP47 inhibition may be for prevention or treatment of cancer, which can be achieved by inhibiting HSP47.
- the cancer may be at least one selected from the group consisting of breast cancer, colorectal cancer, and cancer-related fibrosis.
- the HSP47 inhibition may be for the treatment of inflammatory diseases through inhibition of the secretion of proinflammatory substances that can be achieved by inhibiting HSP47.
- the inflammatory disease may be an autoinflammatory disease and an autoimmune disease associated with an increase in MCP-1.
- the inflammatory disease is liver cancer, prostate cancer, melanoma, ovarian cancer, neuroinflammatory disease, arteriosclerosis, organ transplantation, dermatitis, atopic dermatitis, asthma, conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia , gastric ulcer, pancreatitis, gastritis, psoriasis, nephropathy, neuroinflammatory disease, myasthenia gravis, Crohn's disease, inflammatory bowel disease, colitis, gout, ankylosing spondylitis, lupus, fibromyalgia, psoriasis, rheumatoid arthritis, osteoarthritis, osteoporosis, hepatitis , Cystitis, nephritis, Sjogren's syndrome, and preferably any one selected from the group consisting of multiple sclerosis, but is not limited thereto.
- the compounds of the present invention inhibit HSP47 activity, it was confirmed that they exhibited an EC 50 of 15.89 to 104.5 ⁇ M for HSP47 or exhibited HSP47 inhibitory activity at a compound concentration of 100 ⁇ M.
- the compounds showed fibrosis inhibitory activity in lung epithelial cells and hepatic stellate cells, and inhibited fibrosis in skin fibroblasts.
- the compounds reduced the blood hyaluronic acid level, which is a biomarker of liver fibrosis, and reduced the content of 4-hydroxyproline in liver tissue, thereby reducing fibrosis. It has been found to reduce collagen deposition according to In addition, the above compounds were found to significantly reduce the area of liver fibrosis by suppressing fibrosis of liver tissue in histological staining.
- the EC 50 for MCP-1 was 1.374 to 17.14 ⁇ M.
- the compounds were shown to inhibit MCP-1 secretion in hepatic stellate cells.
- the pharmaceutical composition may further include a pharmaceutically acceptable diluent or carrier.
- the pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier, and oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, and external preparations according to conventional methods. It can be formulated in the form of suppositories, suppositories and sterile injectable solutions.
- the pharmaceutically acceptable carrier is lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil; and the like.
- diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants are included.
- Solid preparations for oral use include tablets, pills, powders, granules, capsules, etc., and these solid preparations contain at least one or more excipients, for example, starch, calcium carbonate, sucrose or lactose. ), gelatin, and the like, and may include lubricants such as magnesium stearate and talc.
- Oral liquid preparations include suspensions, internal solutions, emulsions, syrups, and the like, and may include diluents such as water and liquid paraffin, wetting agents, sweeteners, aromatics, and preservatives.
- Parenteral preparations include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories.
- non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and ethyl injectable esters such as oleate; and the like.
- suppositories witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogelatin, and the like may be used.
- the dosage of the compound of Formula I contained in the pharmaceutical composition of the present invention varies depending on the condition and weight of the patient, the severity of the disease, the drug type, the route and period of administration, but can be appropriately selected by those skilled in the art. there is.
- the compound of Formula I may be administered in a dose of 0.0001 to 1000 mg/kg per day, preferably 0.01 to 1000 mg/kg, and the administration may be administered once or divided into several times a day.
- the pharmaceutical composition of the present invention may include the compound of Formula I in an amount of 0.001 to 90% by weight based on the total weight of the composition.
- the pharmaceutical composition of the present invention is administered to mammals such as rats, mice, livestock, and humans through various routes, for example, oral, intraperitoneal, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection. can be administered by mammals such as rats, mice, livestock, and humans through various routes, for example, oral, intraperitoneal, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection. can be administered by mammals such as rats, mice, livestock, and humans through various routes, for example, oral, intraperitoneal, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection. can be administered by various routes, for example, oral, intraperitoneal, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection. can be administered by various routes, for example, oral, intraperitoneal, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural
- the pharmaceutical composition of the present invention may contain a pharmaceutically acceptable carrier or diluent, and may be prepared according to conventional methods, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, oral formulations, external preparations, It can be formulated in the form of suppositories and sterile injectable solutions.
- the pharmaceutically acceptable carrier is lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil; and the like.
- diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants are included.
- Oral solid preparations include tablets, pills, powders, granules, capsules, etc., and these solid preparations contain at least one or more excipients, for example, starch, calcium carbonate, sucrose or lactose. ), gelatin, and the like, and may include lubricants such as magnesium stearate and talc.
- Oral liquid preparations include suspensions, internal solutions, emulsions, syrups, and the like, and may include diluents such as water and liquid paraffin, wetting agents, sweeteners, aromatics, and preservatives.
- Parenteral preparations include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories.
- non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and ethyl injectable esters such as oleate; and the like.
- a base for the suppository witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogelatin, and the like may be used.
- composition of the present invention can be administered through various routes to mammals such as livestock and humans, for example, oral, dermal, subcutaneous, intramuscular, intravenous, intraperitoneal, intrarectal, intrauterine intrathecal or intracerebrovascular injection, topical It can be administered by intravenous administration.
- the composition of the present invention may be formulated in various forms such as tablets, capsules, aqueous solutions or suspensions.
- carriers such as lactose and corn starch and lubricants such as magnesium stearate may usually be added.
- lactose and/or dried corn starch may be used as diluents.
- the active ingredient may be combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavoring agents may be added.
- emulsifying and/or suspending agents may be added for intramuscular, intraperitoneal, subcutaneous and intravenous administration.
- sterile solutions of the active ingredients are usually prepared, the pH of the solutions suitably adjusted and buffered.
- the total concentration of solutes should be adjusted to impart isotonicity to the formulation.
- the composition according to the present invention may be in the form of an aqueous solution containing a pharmaceutically acceptable carrier such as saline having a pH of 7.4. The solution can be introduced into the patient's intramuscular bloodstream by local injection.
- the dose of the active ingredient contained in the pharmaceutical composition of the present invention varies depending on the condition and weight of the patient, the severity of the disease, the type of active ingredient, the route and period of administration, and may be appropriately adjusted according to the patient.
- the active ingredient may be administered at a dose of 0.0001 to 1000 mg/kg per day, preferably 0.01 to 100 mg/kg, and the administration may be administered once or several times a day.
- the pharmaceutical composition of the present invention may include the active ingredient in a weight percentage of 0.001 to 90% based on the total weight of the composition.
- Step A To a reaction flask containing 2-hydroxy-4-chlorobenzaldehyde (2 g), potassium carbonate (1.5 equivalent), and anhydrous acetone (20 mL), 1.2 equivalent of chloroacetone was added dropwise over 10 minutes, and then , The reaction solution was stirred under reflux for 3 hours. After completion of the reaction, the solid was removed by filtration, and the filtered liquid was dried over anhydrous magnesium sulfate, filtered, concentrated, and separated by column chromatography to obtain 2-acetylbenzofuran ( 1-1 ) (1.99 g, 78% yield) got
- Step B Compound 1-1 (1.99 g, 0.011 mol) was added with 6 equivalents of 80% hydrazine (monohydrate) and diethylene glycol (48 mL), stirred at 150 ° C. for 30 min, then 3 equivalents of potassium Hydroxide was added slowly dropwise over 10 minutes. The reaction solution was stirred under reflux for 3 hours, cooled to room temperature, diluted with water (100 mL), and extracted with ethyl acetate (120 mL x 3).
- the ethyl acetate layer was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and separated by column chromatography to obtain the target compound ( 1-2 , 1.3 g, 72%).
- Step C Compound 1-2 (1.3 g, 0.0081 mol) was dissolved in anhydrous CS2 (20 vol), cooled to 0° C., and then 4-methoxybenzoyl chloride (1.5 eq.) was added and stirred for 5 minutes.
- tin (IV) chloride chloride, 1.5 equivalent
- the extracted organic layer was washed sequentially with 1N hydrochloric acid solution (50 mL), 1N aqueous sodium hydroxide solution (50 mL), and brine (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and filtered. It was separated by chromatography to obtain the target compound ( 1-3 , 1.98 g, 83%).
- Step D After dissolving compound 1-3 (1.98 g, 0.0067 mol) in N, N-dimethylformamide (20 mL), 2.5 equivalents of sodium ethanethiolate (NaSEt) was added at room temperature, and the reaction solution was It was stirred at 100 °C for 2 hours. After completion of the reaction, after dilution by slowly adding aqueous ammonium chloride solution (100 mL), extraction with dichloromethane (100 mL x 2), washing the extract with brine (80 mL), drying the organic layer with anhydrous sodium sulfate and filtering. Then, the mixture was concentrated and separated by column chromatography to obtain the target compound ( 1-4 , 1.68 g, 89%).
- NaSEt sodium ethanethiolate
- Step E After dissolving compound 1-4 (100 mg, 0.35 mmol) in glacial acetic acid (6 mL) and water (2 mL), 2.2 equivalents of bromine diluted with glacial acetic acid (1.5 mL) and water (0.5 mL) was added to 15 After adding dropwise for 20 minutes, the reaction solution was stirred at room temperature for 20 hours. After completion of the reaction, the reaction solution was concentrated and separated by column chromatography to obtain the target compound (1, 86 mg, 55% yield).
- Step A - Step E Compound 2 was obtained in a similar manner to the AE step of Example 1.
- Step A - Step E Compound 3 was obtained in a similar manner to the AE step of Example 1.
- Step A - Step E Compound 4 was obtained in a similar manner to the AE step of Example 1.
- Step A - Step E Compound 5 was obtained in a similar manner to the AE step of Example 1.
- Step A - Step E Compound 6 was obtained in a similar manner to the AE step of Example 1.
- Step A - Step E Compound 7 was obtained in a similar manner to the AE step of Example 1.
- Step A - Step D Compound 8-4 was obtained in a similar manner to the AD step of Example 1.
- Step E After dissolving compound 8-4 (100 mg, 0.35 mmol) in methanol (3 mL), silver nitrate (2.5 equivalents) was added, followed by iodine (2.5 equivalents), and the mixture was stirred at room temperature for 20 hours. After completion of the reaction, the solid was filtered, the filtrate was concentrated, and separated by column chromatography to obtain the target compound ( 8 , 121 mg, 64% yield).
- Step A - Step E Compound 9 was obtained in a similar manner to the AE step of Example 8.
- Step A - Step E Compound 10 was obtained in a similar manner to the AE step of Example 8.
- Step A - Step E Compound 11 was obtained in a similar manner to the AE step of Example 8.
- Step A - Step E Compound 12 was obtained in a similar manner to the AE step of Example 8.
- Step A - Step E Compound 13 was obtained in a similar manner to the AE step of Example 8.
- Step A - Step E Compound 14 was obtained in a similar manner to the AE step of Example 8.
- Step A - Step E Compound 15 was obtained in a similar manner to the AE step of Example 8.
- Step C - Step E Compound 16 was obtained in a similar manner to the CE step of Example 8.
- Step F After dissolving 4-bromosalicylaldehyde (5 g, 32 mmol) in anhydrous acetonitrile (50 mL), 1.5 equivalents of potassium carbonate (1.5 equivalents) were added, followed by 1.5 equivalents of methyl 2-bromopropionic acid. was added dropwise over 10 minutes. After the reaction solution was stirred at room temperature for 6 hours, the resulting solid was filtered, and the filtrate was concentrated. Then, an aqueous solution of lithium hydroxide (1N, 30 mL) and tetrahydrofuran (30 mL) were added and the mixture was stirred under reflux for 5 hours. .
- Step G Compound 17-1 (3.5 g, 15.3 mmol) was added with sodium acetate (5 equivalents), acetic anhydride (40 mL), and glacial acetic acid (20 mL), and the mixture was stirred at 150 °C for 6 hours. After completion of the reaction, the mixture was cooled to room temperature, diluted with water (150 mL), and extracted with ethyl acetate (3 ⁇ 120 mL).
- the extract was washed sequentially with aqueous sodium bicarbonate solution (100 mL) and brine (100 mL), the organic layer was dried over anhydrous sulfuric acid and filtered, and the filtrate was concentrated and separated by column chromatography to obtain the target compound ( 17-2 , 1.77 g, 55% yield) was obtained.
- Step H After dissolving compound 17-2 (1.77 g, 8.44 mol) in anhydrous 1,4-dioxane (18 mL), 4 M hydrochloric acid and 1,4-dioxane solution (5 equivalents) was added and stirred under reflux for 16 hours. did After completion of the reaction, the reaction solution was slowly added to 200 mL of water, followed by extraction with ethyl acetate (100 mL x 3).
- Step I After dissolving compound 17-3 (1.16 g, 6.9 mmol) in methanol (18 mL) and cooling to 0 ° C, sodium borohydride (3 equivalents) was slowly added dropwise over 15 minutes. After stirring the reaction solution at room temperature for 2 hours, cold water (20 mL) was added, and then extracted with dichloromethane (100 mL ⁇ 2). The extract was washed with water (50 mL) and brine (50 mL) sequentially, the organic layer was dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated and separated by column chromatography to obtain the target compound 17-4 (0.918 g). got it
- Step J After dissolving compound 17-4 (0.918 g) in 1,4-dioxane (10 mL), a solution of 1,4-dioxane hydrochloric acid (5 equivalents) was added and stirred under reflux for 6 hours. After completion of the reaction, the mixture was cooled to room temperature, diluted with water (30 mL), and extracted with ethyl acetate (3 ⁇ 120 mL). The extract was washed with an aqueous solution of sodium bicarbonate (20 mL), the organic layer was dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated and separated by column chromatography to obtain the target compound ( 17-5 , 0.641 g, 61% in 2 steps) yield) was obtained.
- Step K After dissolving compound 17-5 (0.641 g, 4.2 mmol) in anhydrous CS2 (10 mL), cooling to 0 ° C, 4-methoxybenzoyl chloride (1.5 equivalent) was added, and tin (IV) chloride ( 1.5 eq) was added dropwise over 5 minutes. After the reaction solution was stirred at room temperature for 24 hours, diluted with cold water (200 mL), the formed solid was filtered, and the aqueous layer was extracted with dichloromethane (90 mL ⁇ 2).
- the extract was sequentially separated with 1 mol aqueous hydrochloric acid solution (20 mL), 1 mol aqueous sodium hydroxide solution (20 mL), and brine (30 mL), the organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and subjected to column chromatography.
- the target compound ( 17-6 , 0.986 g, 78% yield) was obtained.
- Step L Compound 17-6 (0.986 g, 3.2 mmol) was dissolved in anhydrous dichloromethane (10 mL), cooled to -78 ° C, and boron tribromide (1 mol dichloromethane solution, 5 equivalents) was added. After stirring the reaction solution at room temperature for 20 hours, cold water (10 mL) was slowly added thereto, followed by extraction with dichloromethane (30 mL ⁇ 2).
- the extract was washed with water (30 mL) and brine (30 mL) sequentially, the organic layer was dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated and separated by column chromatography to obtain the target compound ( 17-7 , 0.856 g, 91% yield) was obtained.
- Step M Compound 17 was used to obtain the target compound 17 in a similar manner to Step E of Example 25.
- Step F - Step M Compound 18 was obtained in a similar manner to the FM step of Example 17.
- Step M Compound 19 was obtained in a similar manner to Step E of Example 8 using Compound 19-7 .
- Step A - Step E Compound 20 was obtained in a similar manner to the AE step of Example 1.
- Step A - Step E Compound 21 was obtained in a similar manner to the AE step of Example 1.
- Example 22 (3,5-dibromo-4-hydroxyphenyl)(2-ethyl-6-(trifluoromethyl)benzofuran-3-yl)methanone [(3,5-dibromo-4 -hydroxyphenyl)(2-ethyl-6-(trifluoromethyl) benzofuran-3-yl)methanone]
- Step A - Step E Compound 22 was obtained in a similar manner to the AE step of Example 1.
- Step A - Step E Compound 23 was obtained in a similar manner to the AE step of Example 1.
- Example 24 (3,5-dibromo-4-hydroxyphenyl)(2-ethyl-4-fluorobenzofuran-3-yl)methanone [(3,5-dibromo-4-hydroxyphenyl)( 2-ethyl-4-fluorobenzofuran-3-yl) methanone]
- Step A - Step E Compound 24 was obtained in a similar manner to the AE step of Example 1.
- HSP47 activity was evaluated as the extent to which fibril formation was inhibited by adding HSP47 protein (GenScript US) at a concentration of 9.45 ⁇ g/ml.
- the degree of HSP47 inhibition was expressed as a percentage or EC 50 by including the test substance at a concentration of 100 ⁇ M to 1 ⁇ M.
- liver stellate cells Liver stellate LX-2, Elabscience, CH
- lung epithelial cells A549) or skin KEL FIB (ATCC, US) cells in a 24-well tissue culture plate for 18 hours
- TGF-beta 10 After ng/ml treatment, it was incubated for 24 hours with the test compound. Cells were washed with PBS, fixed with Bouin's solution, and then washed twice with distillation. After staining the fixed cells with Sirius red for 2 hours, changes in cell morphology were observed, followed by washing with HCl 0.01 N solution and extracting Sirius red combined with collagen with NaOH 0.1 N solution. After that, it was quantified at 570 nm wavelength. The efficacy of each compound in inhibiting collagen production was expressed as a percentage or EC 50 .
- LX-2 cells a hepatic stellate cell line, were cultured in a 24-well tissue culture plate for 18 hours, treated with 10 ng/ml of TGF-beta, and then cultured with 30 to 1 ⁇ M of test substance for 24 hours.
- MCP-1 protein secreted in the cell culture medium was quantified using an ELISA reagent (RnD, USA).
- the EC 50 value was obtained by using prism software (Graphpad, ver 9.4 USA) for MCP-1 quantitative values resulting from each test substance treatment.
- Example HSP47 inhibitory activity EC 50 , ⁇ M % inhibition at 100 ⁇ M
- Table 2 shows the results of inhibition of hepatic stellate cell fibrosis.
- Example LX-2 cell EC 50 ⁇ M % inhibition at 10 ⁇ M One 2.998 - 2 - 65.10 3 1.374 - 4 5.552 - 5 4.727 - 6 17.14 - 7 10.88 - 8 - 67.9 9 - 111.12 10 - 127.72 11 - 78.30 12 8.151 - 14 - 90.62 17 3.699 - 18 4.667 - 19 - 72.6 20 4.018 - 21 3.067 - 22 2.805 - 23 3.393 - 24 3.595 -
- Table 4 below shows the results of inhibition of skin fibroblast fibrosis.
- Table 5 shows the results of inhibition of MCP-1 secretion in LX-2 hepatic stellate cells by treatment with the test substance.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Example | HSP47 저해활성 EC 50 ,μM | % inhibition at 100μM |
1 | - | 23.31 |
2 | 40.75 | - |
3 | - | 26.28 |
4 | 73.04 | - |
5 | 37.76 | - |
6 | 80.82 | - |
7 | - | 18.15 |
8 | 37.1 | - |
9 | - | 52.38 |
10 | - | 41.77 |
11 | - | 69.24 |
12 | 73.14 | - |
13 | 49.14 | - |
14 | 15.89 | - |
15 | 48.26 | - |
16 | 31.4 | - |
17 | - | 19.5 |
18 | - | 75.2 |
19 | - | 68.19 |
20 | 49.23 | - |
21 | 5.524 | - |
22 | 32.09 | - |
23 | 71 | - |
24 | 104.5 | - |
Example | LX-2 cell EC 50 μM | % inhibition at 10μM |
1 | 2.998 | - |
2 | - | 65.10 |
3 | 1.374 | - |
4 | 5.552 | - |
5 | 4.727 | - |
6 | 17.14 | - |
7 | 10.88 | - |
8 | - | 67.9 |
9 | - | 111.12 |
10 | - | 127.72 |
11 | - | 78.30 |
12 | 8.151 | - |
14 | - | 90.62 |
17 | 3.699 | - |
18 | 4.667 | - |
19 | - | 72.6 |
20 | 4.018 | - |
21 | 3.067 | - |
22 | 2.805 | - |
23 | 3.393 | - |
24 | 3.595 | - |
Example | % inhibition at 30μM | % inhibition at 10μM |
13 | 72.46 | 65.16% |
15 | 96.25 | - |
16 | - | 64.315 |
Example | KEL FIB cell EC 50 μM |
9 | 3.281 |
Example | LX-2 cell EC 50 μM |
1 | 4.61 |
3 | 2.211 |
4 | 8.687 |
5 | 3.557 |
6 | 10.16 |
7 | 2.85 |
17 | 3.733 |
18 | 3.008 |
20 | 2.102 |
21 | 2.801 |
Claims (16)
- 제1항에 있어서, 상기 R1 및 R2가 브로모 또는 요오드인 것을 특징으로 하는 화합물 또는 이의 약학적으로 허용가능한 염.
- 제1항에 있어서, 상기 R3가 수소, 메틸 및 에틸로 이루어진 군으로부터 선택된 치환기인 것을 특징으로 하는 화합물 또는 이의 약학적으로 허용가능한 염.
- 제1항에 있어서, 상기 Ra가 수소, 메틸, 플루오로 및 클로로로 이루어진 군으로부터 선택된 치환기인 것을 특징으로 하는 화합물 또는 이의 약학적으로 허용가능한 염.
- 제1항에 있어서, 상기 Rb가 수소, 메틸, 에틸 및 브로모로 이루어진 군으로부터 선택된 치환기인 것을 특징으로 하는 화합물 또는 이의 약학적으로 허용가능한 염.
- 제1항에 있어서, 상기 Rc가 수소, 메틸, 에틸, 트리플루오로메틸, 클로로 및 브로모로 이루어진 군으로부터 선택된 치환기인 것을 특징으로 하는 화합물 또는 이의 약학적으로 허용가능한 염.
- 제1항에 있어서, 상기 Rd가 수소, 메틸, 에틸, 플루오로, 클로로 및 브로모로 이루어진 군으로부터 선택된 치환기인 것을 특징으로 하는 화합물 또는 이의 약학적으로 허용가능한 염.
- 제1항에 있어서, 상기 화학식 I로 표시되는 벤조퓨라닐 히드록시페닐 메타논 유도체 화합물이(4-클로로-2-에틸벤조퓨란-3-일)(3,5-디브로모-4-히드록시페닐)메타논,(3,5-디브로모-4-히드록시페닐)(2-에틸-5-메틸벤조퓨란-3-일)메타논,(3,5-디브로모-4-히드록시페닐)(2,6-디에틸벤조퓨란-3-일)메타논,(3,5-디브로모-4-히드록시페닐)(2-에틸-7-메틸벤조퓨란-3-일)메타논,(7-클로로-2-에틸벤조퓨란-3-일)(3,5-디브로모-4-히드록시페닐)메타논,(7-브로모-2-에틸벤조퓨란-3-일)(3,5-디브로모-4-히드록시페닐)메타논,(3,5-디브로모-4-히드록시페닐)(2-에틸-7-플루오로벤조퓨란-3-일)메타논,(2-에틸-5-메틸벤조퓨란-3-일)(4-히드록시-3,5-디요오드페닐)메타논,(5-브로모-2-에틸벤조퓨란-3-일)(4-히드록시-3,5-디요오드페닐)메타논,(2-에틸-6-메틸벤조퓨란-3-일)(4-히드록시-3,5-디요오드페닐)메타논,(6-브로모-2-에틸벤조퓨란-3-일)(4-히드록시-3,5-디요오드페닐)메타논,(6-클로로-2-에틸벤조퓨란-3-일)(3,5-디브로모-4-히드록시페닐)메타논,(2-에틸-7-메틸벤조퓨란-3-일)(4-히드록시-3,5-디요오드페닐)메타논,(7-클로로-2-에틸벤보퓨란-3-일)(4-히드록시-3,5-디요오드페닐)메타논,(7-브로모-2-에틸벤조퓨란-3-일)(4-히드록시-3,5-디요오드페닐)메타논,벤조퓨란-3-일(3,5-디브로모-4-히드록시페닐)메타논,(6-브로모-2-메틸벤조퓨란-3-일)(3,5-디브로모-4-히드록시페닐)메타논,(5-브로모-2-메틸벤조퓨란-3-일)(3,5-디브로모-4-히드록시페닐)메타논,(6-클로로-2-메틸벤조퓨란-3-일)(4-히드록시-3,5-디요오드페닐)메타논,(3,5-디브로모-4-히드록시페닐)(2,5-디에틸벤조퓨란-3-일)메타논,(3,5-디브로모-4-히드록시페닐)(2,7-디에틸벤조퓨란-3-일)메타논,(3,5-디브로모-4-히디록시페닐)(2-에틸-6-(트리플루오로메틸)벤조퓨란-3-일)메타논,(3,5-디브로모-4-히드록시페닐)(2-에틸-4-메틸벤조퓨란-3-일)메타논,(3,5-디브로모-4-히드록시페닐)(2-에틸-4-플루오로벤조퓨란-3-일)메타논,으로 이루어진 군으로부터 선택되는 어느 하나의 화합물인 것을 특징으로 하는 화합물 또는 이의 약학적으로 허용가능한 염.
- 제1항 내지 제8항 중 어느 한 항의 벤조퓨라닐 히드록시페닐 메타논 유도체 화합물, 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 HSP47 억제용 약학 조성물.
- 제9항에 있어서, 상기 HSP47 억제용이 섬유증의 예방 또는 치료용인 것을 특징으로 하는 HSP47 억제용 약학 조성물.
- 제10항에 있어서. 상기 섬유증이 간경화, 폐섬유화, 켈로이드(keloid), 과증식성 흉터(hypertrophic scar) 및 신장섬유화(사구체 경화증)로 이루어진 군으로부터 선택된 1 이상인 것을 특징으로 하는 HSP47 억제용 약학 조성물.
- 제9항에 있어서, 상기 HSP47 억제용이 암의 예방 또는 치료용인 것을 특징으로 하는 HSP47 억제용 약학 조성물.
- 제12항에 있어서, 상기 암이 유방암, 대장암 및 암-관련 섬유화증으로 이루어진 군으로부터 선택된 1 이상인 것을 특징으로 하는 HSP47 억제용 약학 조성물.
- 제9항에 있어서, 상기 HSP47 억제용이 염증성 질환의 예방 또는 치료용인 것을 특징으로 하는 HSP47 억제용 약학 조성물.
- 제14항에 있어서, 상기 염증성 질환이 간암, 전립선암, 흑색종, 난소암, 신경염증성 질환, 동맥경화증, 장기이식, 피부염, 아토피 피부염, 천식, 결막염, 치주염, 비염, 중이염, 인후염, 편도염, 폐렴, 위궤양, 췌장염, 위염, 건선, 신병증, 신경염증성 질환, 중증 근무력증, 크론병, 염증성 장질환, 대장염, 통풍, 강직성 척추염, 루프스, 섬유근통(fibromyalgia), 건선, 류마티스 관절염, 골관절염, 골다공증, 간염, 방광염, 신장염, 쇼그렌 증후군 및 다발성경화증으로 이루어진 군으로부터 선택된 1 이상인 것을 특징으로 하는 HSP47 억제용 약학 조성물.
- 하기 화학식 I-1의 화합물로부터 친핵치환반응에 의해 하기 화학식 I-2의 화합물을 제조하는 단계;상기 얻어진 화학식 I-2의 화합물을 환원시켜 하기 화학식 I-3의 화합물을 제조하는 단계;상기 얻어진 화학식 I-3의 화합물을 4-아니조일 클로라이드와 반응시켜 하기 화학식 I-4의 화합물을 제조하는 단계;상기 얻어진 화학식 I-4의 화합물의 메톡시의 메틸을 제거하여 히드록시 치환기를 갖는 하기 화학식 I-5의 화합물을 제조하는 단계; 및상기 얻어진 화학식 I-5의 화합물로부터 하기 화학식 I의 화합물을 얻는 단계를 포함하는, 하기 화학식 I로 표시되는 벤조퓨라닐 히드록시페닐 메타논 유도체 화합물, 또는 이의 약학적으로 허용가능한 염의 제조방법:<화학식 I><화학식 I-1><화학식 I-2><화학식 I-3><화학식 I-4><화학식 I-5>상기 화학식 I, 화학식 I-1, 화학식 I-2, 화학식 I-3, 화학식 I-4 및 화학식 I-5에서, R1, R2, R3, Ra, Rb, Rc 및 Rd은 제1항에서 정의한 바와 동일하다.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2022359537A AU2022359537A1 (en) | 2021-10-07 | 2022-10-07 | Novel benzofuranyl hydroxyphenyl methanone derivative compound or pharmaceutically acceptable salt thereof |
CA3232204A CA3232204A1 (en) | 2021-10-07 | 2022-10-07 | Novel benzofuranyl hydroxyphenyl methanone derivative compound or pharmaceutically acceptable salt thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0132806 | 2021-10-07 | ||
KR20210132806 | 2021-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023059121A1 true WO2023059121A1 (ko) | 2023-04-13 |
Family
ID=85804464
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/014361 WO2023058975A1 (ko) | 2021-10-07 | 2022-09-26 | 벤조퓨라닐 히드록시페닐 메타논 유도체를 포함하는 hsp47 억제용 약학 조성물 |
PCT/KR2022/015097 WO2023059121A1 (ko) | 2021-10-07 | 2022-10-07 | 신규한 벤조퓨라닐 히드록시페닐 메타논 유도체 화합물 또는 이의 약학적으로 허용가능한 염 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/014361 WO2023058975A1 (ko) | 2021-10-07 | 2022-09-26 | 벤조퓨라닐 히드록시페닐 메타논 유도체를 포함하는 hsp47 억제용 약학 조성물 |
Country Status (4)
Country | Link |
---|---|
KR (2) | KR20230050232A (ko) |
AU (1) | AU2022359537A1 (ko) |
CA (1) | CA3232204A1 (ko) |
WO (2) | WO2023058975A1 (ko) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010031859A1 (en) * | 2008-09-18 | 2010-03-25 | Centre National De La Recherche Scientifique (Cnrs) | Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis |
WO2012104655A2 (en) * | 2011-02-04 | 2012-08-09 | Biocopea Limited | Compostions and methods for treating chronic inflammation and inflammatory diseases |
CN102718735A (zh) * | 2012-05-28 | 2012-10-10 | 沈阳药科大学 | 2-乙基-3-(4-羟基)苯甲酰基苯并呋喃类化合物、组合物及其制备方法 |
WO2019195118A1 (en) * | 2018-04-03 | 2019-10-10 | Children's Hospital Medical Center | Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension |
WO2020232156A1 (en) * | 2019-05-14 | 2020-11-19 | Arthrosi Therapeutics, Inc. | Compound for treating gout or hyperuricemia |
KR102404883B1 (ko) * | 2020-11-30 | 2022-06-07 | (주)이노보테라퓨틱스 | 벤즈브로마론을 포함하는 켈로이드 또는 비대흉터 예방 또는 치료용 약학 조성물 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111265511A (zh) * | 2020-04-07 | 2020-06-12 | 河南大学 | 苯溴马隆作为fxr激动剂的应用 |
-
2022
- 2022-09-26 WO PCT/KR2022/014361 patent/WO2023058975A1/ko unknown
- 2022-09-26 KR KR1020220121606A patent/KR20230050232A/ko unknown
- 2022-10-06 KR KR1020220127758A patent/KR20230050255A/ko not_active Application Discontinuation
- 2022-10-07 CA CA3232204A patent/CA3232204A1/en active Pending
- 2022-10-07 AU AU2022359537A patent/AU2022359537A1/en active Pending
- 2022-10-07 WO PCT/KR2022/015097 patent/WO2023059121A1/ko active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010031859A1 (en) * | 2008-09-18 | 2010-03-25 | Centre National De La Recherche Scientifique (Cnrs) | Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis |
WO2012104655A2 (en) * | 2011-02-04 | 2012-08-09 | Biocopea Limited | Compostions and methods for treating chronic inflammation and inflammatory diseases |
CN102718735A (zh) * | 2012-05-28 | 2012-10-10 | 沈阳药科大学 | 2-乙基-3-(4-羟基)苯甲酰基苯并呋喃类化合物、组合物及其制备方法 |
WO2019195118A1 (en) * | 2018-04-03 | 2019-10-10 | Children's Hospital Medical Center | Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension |
WO2020232156A1 (en) * | 2019-05-14 | 2020-11-19 | Arthrosi Therapeutics, Inc. | Compound for treating gout or hyperuricemia |
KR102404883B1 (ko) * | 2020-11-30 | 2022-06-07 | (주)이노보테라퓨틱스 | 벤즈브로마론을 포함하는 켈로이드 또는 비대흉터 예방 또는 치료용 약학 조성물 |
Also Published As
Publication number | Publication date |
---|---|
AU2022359537A1 (en) | 2024-04-04 |
KR20230050232A (ko) | 2023-04-14 |
WO2023058975A1 (ko) | 2023-04-13 |
CA3232204A1 (en) | 2023-04-13 |
KR20230050255A (ko) | 2023-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020384121B2 (en) | GLP-1 receptor agonist and use thereof | |
WO2011043568A2 (en) | Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | |
WO2016064082A2 (ko) | 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도 | |
WO2021256861A1 (ko) | 신규한 산 분비 억제제 및 이의 용도 | |
WO2019168237A1 (ko) | 신규 화합물 및 이를 유효성분으로 함유하는 섬유증 또는 비알코올성 지방간염의 예방, 개선 또는 치료용 조성물 | |
WO2021060890A1 (ko) | 헤테로아릴아미도피리딘올 유도체 및 이를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약학적 조성물. | |
WO2023195791A1 (ko) | 신규한 크로마논 화합물을 유효성분으로 포함하는 다발성골수종의 예방 또는 치료용 조성물 | |
WO2016093554A2 (ko) | 신규한 4-(아릴)-n-(2-알콕시티에노[3,2-b]피라진-3-일)-피페라진-1-카복스아미드 유도체 및 이의 항증식 효과 | |
WO2011122815A2 (en) | Novel quinoxaline derivatives | |
WO2018056621A1 (ko) | 신규한 이미다졸일 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 | |
WO2015060613A1 (en) | Novel antifungal oxodihydropyridinecarbohydrazide derivative | |
WO2023059121A1 (ko) | 신규한 벤조퓨라닐 히드록시페닐 메타논 유도체 화합물 또는 이의 약학적으로 허용가능한 염 | |
WO2012148140A2 (ko) | 혈관 신생 억제 및 항산화 효과를 가지는 이미다졸계 알칼로이드 유도체 및 이의 제조방법 | |
WO2021149900A1 (ko) | 이치환 아다만틸 유도체, 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 암 성장 억제용 약학적 조성물 | |
WO2021096314A1 (ko) | 신규한 벤즈이미다졸 유도체 및 이의 용도 | |
WO2020017878A1 (en) | Novel catechol derivatives or salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same | |
WO2021137665A1 (ko) | Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물 및 이의 용도 | |
WO2016108319A1 (ko) | 신규 레바미피드 전구체의 염 및 이의 용도 | |
WO2022255765A1 (ko) | 신규 불소-치환 플라보노이드 유도체 및 이를 포함하는 알러지성 질환의 예방 또는 치료용 약학적 조성물 | |
WO2021107656A2 (ko) | 신규한 퀘르세틴 리독스 유도체 및 bet 억제제로서의 용도 | |
WO2024071629A1 (ko) | 신규한 플루오렌 유도체 및 이의 용도 | |
WO2023229099A1 (ko) | 벤조퓨라닐 히드록시페닐 메타논 옥심 유도체 및 이의 용도 | |
WO2019098785A1 (ko) | 7-아미노-1h-인돌-5-카르복사미드 유도체 및 이의 용도 | |
WO2023090908A1 (ko) | 신규 플라보노이드 유도체 및 이를 유효성분으로 포함하는 대사성 질환의 예방 또는 치료용 약학 조성물 | |
WO2015111967A1 (ko) | 페녹시아크릴 유도체 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22878942 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022359537 Country of ref document: AU Ref document number: 3232204 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022359537 Country of ref document: AU Date of ref document: 20221007 Kind code of ref document: A |